Compare Autodesk Inc (ADSK) vs Citius Pharmaceuticals Inc (CTXR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Autodesk Inc vs Citius Pharmaceuticals Inc — how do they compare? Autodesk Inc trades at $246.15 (market cap $53.12B), while Citius Pharmaceuticals Inc trades at $0.73 (market cap $20.01M). The key difference: Autodesk Inc is far larger — about 2654.7× Citius Pharmaceuticals Inc's market cap, and Autodesk Inc is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| ADSK | CTXR | |
|---|---|---|
Market Cap | $53.12B | $20.01M |
Sector | Technology | Health |
52-Week High | $326.79 | $1.82 |
52-Week Low | $187.72 | $0.48 |
Enterprise Value | $52.92B | $16.23M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Autodesk (ADSK) trades at $256.07, up 2.81% with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with revenue growth from $4.4B in 2022 to $6.1B in 2025, net income margin expanding to 19.49%, and consistent earnings beats. Recent news highlights AI investments and upcoming Q2 2027 earnings call on August 27, 2026.
Outlook remains positive with 74.5% analyst buy ratings and $302.23 consensus target offering 18% upside. Key risks include elevated valuation multiples (P/E 36.73) and competitive pressures in design software. The stock's technical strength and fundamental growth trajectory support continued investor interest despite overbought RSI signals.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Autodesk Inc
Founded in 1982, Autodesk is an application software company that serves industries in architecture, engineering, and construction.
Read more on ADSK →About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →
